RTP Mobile Logo
Clinical Investigator Perspectives on the Management of Renal Cell Carcinoma (Faculty Presentation)
Released June 2022

Featuring a slide presentation and related discussion from Dr Brian Rini. Published June 2, 2022. (Faculty Presentation)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of renal cell carcinoma.

    LEARNING OBJECTIVES

    • Evaluate recently presented data with adjuvant anti-PD-1 antibody therapy for patients with renal cell carcinoma (RCC) at high risk for recurrence after nephrectomy, and consider the potential role of this treatment strategy.
    • Effectively apply evidence-based research findings and other clinical and biologic factors in the best practice selection of first-line therapy for patients with metastatic RCC (mRCC).
    • Recall the underlying research database supporting the FDA approval of anti-PD-1/anti-CTLA-4 combination therapy as first-line treatment for mRCC, and develop strategies to appropriately integrate this approach into patient care.
    • Appraise available clinical trial data evaluating combinations of anti-PD-1/PD-L1 antibodies with multikinase inhibitors for previously untreated mRCC, and counsel patients regarding the risks and benefits of these novel regimens.
    • Develop a rational therapeutic approach to the sequencing of systemic therapies for patients with advanced RCC who experience disease progression on first-line treatment, incorporating multikinase inhibitors, mTOR inhibitors, immunotherapeutic agents and other therapies.
    • Recognize side effects and toxicities commonly associated with approved and investigational agents and regimens for RCC, and use this information to develop supportive care plans for patients.
    • Recall available and emerging data with other investigational agents and strategies currently in testing for RCC, and where applicable, refer eligible patients for clinical trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/Renal22/Presentation/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Thomas E Hutson, DO, PharmD
    Director, GU Oncology Program
    Co-Director, Urologic Cancer Research and Treatment Center
    Texas Oncology
    Charles A Sammons Cancer Center
    Baylor University Medical Center
    Professor of Medicine
    Texas A&M HSC College of Medicine
    Dallas, Texas

    No relevant conflicts of interest to disclose.

    Brian I Rini, MD
    Chief of Clinical Trials
    Vanderbilt-Ingram Cancer Center
    Ingram Professor of Medicine
    Division of Hematology/Oncology
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Advisory Committee and Consulting Agreements: 3DMedicines Corporation, Alkermes, Aravive Inc, Arrowhead Pharmaceuticals Inc, Aveo Pharmaceuticals, Bristol-Myers Squibb Company, Compugen, Corvus Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Merck, Nikang Therapeutics, Pfizer Inc, Sanofi Genzyme, Shionogi Inc, Surface Oncology; Contracted Research: Aravive Inc, Arrowhead Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, F Hoffmann-La Roche Ltd, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mirati Therapeutics, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Surface Oncology; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc and Merck.

    Release date: June 2022
    Expiration date: June 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):